Vanguard Group
XFOR icon

Vanguard Group’s X4 Pharmaceuticals XFOR Stock Holding History

Vanguard Group’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$13.7M Buy
3,423,662
+3,013,177
+734% +$10.9M ﹤0.01% 2800
2025
Q3 		$1.4M Buy
410,485
+178,593
+77% +$461K ﹤0.01% 3681
2025
Q2 		$441K Sell
231,892
-37,025
-14% -$152K ﹤0.01% 3945
2025
Q1 		$1.9M Sell
268,917
-4,446
-2% -$61.2K ﹤0.01% 3507
2024
Q4 		$6.02M Sell
273,363
-7,995
-3% -$127K ﹤0.01% 3192
2024
Q3 		$5.65M Buy
281,358
+5,023
+2% +$105K ﹤0.01% 3225
2024
Q2 		$4.81M Buy
276,335
+15,411
+6% +$504K ﹤0.01% 3274
2024
Q1 		$10.9M Sell
260,924
-6,038
-2% -$168K ﹤0.01% 2912
2023
Q4 		$6.72M Buy
266,962
+6,138
+2% +$149K ﹤0.01% 3164
2023
Q3 		$8.53M Buy
260,824
+1,253
+0.5% +$54.6K ﹤0.01% 2970
2023
Q2 		$15.1M Buy
259,571
+114,761
+79% +$5.9M ﹤0.01% 2716
2023
Q1 		$3.78M Buy
144,810
+25,464
+21% +$747K ﹤0.01% 3432
2022
Q4 		$3.56M Buy
119,346
+12,409
+12% +$588K ﹤0.01% 3451
2022
Q3 		$5.49M Buy
106,937
+83,098
+349% +$2.87M ﹤0.01% 3275
2022
Q2 		$690K Buy
23,839
+2,066
+9% +$78.6K ﹤0.01% 4200
2022
Q1 		$1.14M Sell
21,773
-9,335
-30% -$535K ﹤0.01% 4165
2021
Q4 		$2.14M Sell
31,108
-37
-0.1% -$4.68K ﹤0.01% 4008
2021
Q3 		$4.94M Buy
31,145
+1,224
+4% +$201K ﹤0.01% 3669
2021
Q2 		$5.83M Buy
29,921
+5,368
+22% +$1.35M ﹤0.01% 3514
2021
Q1 		$6.34M Buy
24,553
+54
+0.2% +$14.2K ﹤0.01% 3400
2020
Q4 		$4.73M Buy
24,499
+586
+2% +$115K ﹤0.01% 3386
2020
Q3 		$4.86M Sell
23,913
-108
-0.4% -$25.9K ﹤0.01% 3167
2020
Q2 		$6.72M Sell
24,021
-614
-2% -$168K ﹤0.01% 2954
2020
Q1 		$7.39M Buy
24,635
+612
+3% +$174K ﹤0.01% 2762
2019
Q4 		$7.71M Buy
24,023
+5,959
+33% +$2.14M ﹤0.01% 2981
2019
Q3 		$6.89M Buy
18,064
+637
+4% +$252K ﹤0.01% 3016
2019
Q2 		$7.84M Buy
17,427
+14,551
+506% +$7.4M ﹤0.01% 2990
2019
Q1 		$1.5M Buy
2,876
+1,108
+63% +$611K ﹤0.01% 3527
2018
Q4 		$739K Buy
1,768
+180
+11% +$68.7K ﹤0.01% 3647
2018
Q3 		$463K Hold
1,588
– – ﹤0.01% 3866
2018
Q2 		$1.04M Buy
1,588
+680
+75% +$2.23M ﹤0.01% 3675
2018
Q1 		$3.74M Buy
+908
New +$2.64M ﹤0.01% 3256

Other funds holding XFOR

EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group's XFOR Position: Q4 2025 in Review

Vanguard Group increased its X4 Pharmaceuticals (XFOR) stake by 734% in Q4 2025, buying an estimated $10.9M and bringing the position to 3,423,662 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2800.

Vanguard Group first reported a position in XFOR in Q1 2018 and has held it in 32 quarters since. The position peaked at $15.1M in Q2 2023. 79 funds tracked by Wall St. Rank hold XFOR as of Q4 2025.

  • Vanguard Group held 3,423,662 shares of X4 Pharmaceuticals worth $13.7M as of Q4 2025.
  • Vanguard Group bought 3,013,177 X4 Pharmaceuticals shares in Q4 2025, an estimated $10.9M.
  • X4 Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2800 holding.
  • Vanguard Group first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 32 quarters since.
  • Vanguard Group's X4 Pharmaceuticals position peaked at $15.1M in Q2 2023.
  • 79 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.